Anti-angiogenesis and Preeclampsia in 2016
Purpose of Review
Preeclampsia remains one of the most important complications in pregnancy worldwide. With this review, we aim to give an overview on important research findings over the last years and their effects on current clinical management.
The association between preeclampsia and altered angiogenesis is nowadays widely accepted. Only during the last years, assessment of angiogenic factors such as the soluble fms-like tyrosine kinase-1-to-placental growth factor (sFlt-1/PlGF) ratio has become available to everyday clinical practice with commercially available automated measurements. With these, preeclampsia can be confirmed or ruled out in uncertainty of diagnosis, and a short-term prognosis can be given in patients with symptoms of preeclampsia. Pilot studies show that maternal serum levels of sFlt-1 can be reduced by therapeutic apheresis and that this might prolong pregnancy in case of very early severe preeclampsia.
The automated measurement of the sFlt-1/PlGF ratio is starting to influence clinical management of preeclampsia. Apheresis might offer new treatment options, but still needs to be evaluated in randomized trials.
KeywordsPreeclampsia Anti-angiogenesis Placental growth factor (PlGF) Soluble fms-like tyrosinkinase-1 (sFlt-1)
Compliance with Ethical Standards
Conflict of Interest
Drs. Schrey-Petersen declares no conflicts of interest relevant to this manuscript. Dr. Stepan has received speaker fees from and has worked as a consultant for Roche Diagnostics.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.WHO, Make every mother and child count. Geneva: World Health Report 2005. 2005.Google Scholar
- 2.Knight M K.S., Brocklehurst P, Neilson J, Shakespeare J, Kurinczuk JJ, eds, on behalf of MBRRACEUK. Oxford: National Perinatal Epidemiology Unit, University of Oxford, Saving lives, improving mothers’care—lessons learned to inform future maternity care from the UK and Ireland confidential enquiries into maternal deaths and morbidity 2009–12. 2014.Google Scholar
- 37.• Rana S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012;125(7):911–9. This prospective study in 616 women who presented with suspected preeclampsia showed that the addition of sFlt1/PlGF ratio to hypertension and proteinuria significantly improved the prediction for subsequent adverse outcomes (area under the curve, 0.93 for hypertension, proteinuria, and sFlt1/PlGF versus 0.84 for hypertension and proteinuria alone; P =0.001). Delivery occurred within 2 weeks of presentation in 86.0% of women with an sFlt1/PlGF ratio ≥85 compared with 15.8% of women with an sFlt1/PlGF ratio <85 (hazard ratio, 15.2; 95% confidence interval, 8.0-28.7) PubMedPubMedCentralCrossRefGoogle Scholar
- 40.• Zeisler H, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374(1):13–22. This large prospective, observational study demonstrated that an sFlt-1/PlGF ratio of ≤38 could be used to rule out onset of preeclampsia within 1 week with a negative predictive value of 99.3% in women who presented with symptoms of preeclampsia before 37 weeks of gestation PubMedCrossRefGoogle Scholar
- 41.• Chappell LC, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation. 2013;128(19):2121–31. This prospective multicenter study showed that in women with suspected preeclampsia before 35 weeks onset of preeclampsia within 2 weeks could be ruled out by a PlGF <5th perecentile with a high sensitivity (0.96; 95% CI, 0.89-0.99) and negative predictive value (0.98; 0.93-0.995) PubMedCrossRefGoogle Scholar
- 42.Guidelines, N.. PlGF-based testing to help diagnose suspected preeclampsia (Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1–2-3 test, and Brahms sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio). Published May 2016, N. Guidelines, Editor. 2016.Google Scholar
- 44.Romero R, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008;21(1):9–23.PubMedPubMedCentralCrossRefGoogle Scholar
- 62.Chaiworapongsa T, et al. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med. 2008;21(1):25–40.PubMedCrossRefGoogle Scholar
- 71.• Thadhani R, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation. 2011;124(8):940–50. This small pilot study showed that circulating sFlt-1 levels in the maternal serum could be lowered by extra-corporal removal with a negatively charged adsoprtion column, which might offer the possibility to prolong pregnancy in very preterm preeclampsia. Further studies are needed to study the efficacy and safety of apheresis in this setting PubMedCrossRefGoogle Scholar
- 73.Makris A, Yeung KR, Lim SM, Sunderland N, Heffernan S, Thompson JF, Iliopoulos J, Killingsworth MC, Yong J, Xu B, Ogle RF, Thadhani R, Karumanchi SA, Hennessy A. Placental growth factor reduces blood pressure in a uteroplacental ischemia model of preeclampsia in non-human primates. Hypertension. 2016 Jun;67(6):1263–72.PubMedPubMedCentralCrossRefGoogle Scholar